Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 93

1.

First-line therapy with either bortezomib-melphalan-prednisone or lenalidomide-dexamethasone followed by lenalidomide for transplant-ineligible multiple myeloma patients: a pooled analysis of two randomized trials.

Larocca A, Mina R, Offidani M, Liberati AM, Ledda A, Patriarca F, Evangelista A, Spada S, Benevolo G, Oddolo D, Innao V, Cangialosi C, Bernardini A, Musto P, Amico V, Fraticelli V, Paris L, Giuliani N, Falcone AP, Zambello R, De Paoli L, Romano A, Palumbo A, Montefusco V, Hajek R, Boccadoro M, Bringhen S.

Haematologica. 2019 Jun 27. pii: haematol.2019.220657. doi: 10.3324/haematol.2019.220657. [Epub ahead of print]

2.

Outcome of paraosseous extra-medullary disease in newly diagnosed multiple myeloma patients treated with new drugs.

Montefusco V, Gay F, Spada S, De Paoli L, Di Raimondo F, Ribolla R, Musolino C, Patriarca F, Musto P, Galieni P, Ballanti S, Nozzoli C, Cascavilla N, Ben-Yehuda D, Nagler A, Hajek R, Offidani M, Liberati AM, Sonneveld P, Cavo M, Corradini P, Boccadoro M.

Haematologica. 2019 Jun 20. pii: haematol.2019.219139. doi: 10.3324/haematol.2019.219139. [Epub ahead of print]

3.

Once-weekly versus twice-weekly carfilzomib in patients with newly diagnosed multiple myeloma: a pooled analysis of two phase I/II studies.

Bringhen S, Mina R, Petrucci MT, Gaidano G, Ballanti S, Musto P, Offidani M, Spada S, Benevolo G, Ponticelli E, Galieni P, Cavo M, Di Toritto TC, Di Raimondo F, Montefusco V, Palumbo A, Boccadoro M, Larocca A.

Haematologica. 2019 Aug;104(8):1640-1647. doi: 10.3324/haematol.2018.208272. Epub 2019 Feb 7.

4.

Minimal residual disease by flow cytometry and allelic-specific oligonucleotide real-time quantitative polymerase chain reaction in patients with myeloma receiving lenalidomide maintenance: A pooled analysis.

Gambella M, Omedé P, Spada S, Muccio VE, Gilestro M, Saraci E, Grammatico S, Larocca A, Conticello C, Bernardini A, Gamberi B, Troia R, Liberati AM, Offidani M, Rocci A, Palumbo A, Cavo M, Sonneveld P, Boccadoro M, Oliva S.

Cancer. 2019 Mar 1;125(5):750-760. doi: 10.1002/cncr.31854. Epub 2018 Dec 18.

PMID:
30561775
5.

Continuous therapy in standard- and high-risk newly-diagnosed multiple myeloma: A pooled analysis of 2 phase III trials.

D'Agostino M, De Paoli L, Conticello C, Offidani M, Ria R, Petrucci MT, Spada S, Marcatti M, Catalano L, Gilestro M, Guglielmelli T, Baldini L, Gamberi B, Rizzi R, De Sabbata G, Di Renzo N, Patriarca F, Pezzatti S, Siniscalchi A, Ribolla R, Palumbo A, Montefusco V, Nagler A, Boccadoro M, Gay F.

Crit Rev Oncol Hematol. 2018 Dec;132:9-16. doi: 10.1016/j.critrevonc.2018.09.008. Epub 2018 Sep 14. Review.

PMID:
30447931
6.

Early mortality in myeloma patients treated with first-generation novel agents thalidomide, lenalidomide, bortezomib at diagnosis: A pooled analysis.

Bringhen S, Offidani M, Palmieri S, Pisani F, Rizzi R, Spada S, Evangelista A, Di Renzo N, Musto P, Marcatti M, Vallone R, Storti S, Bernardini A, Centurioni R, Aitini E, Palmas A, Annibali O, Angelucci E, Ferrando P, Baraldi A, Rocco S, Andriani A, Siniscalchi A, De Stefano V, Meneghini V, Palumbo A, Grammatico S, Boccadoro M, Larocca A.

Crit Rev Oncol Hematol. 2018 Oct;130:27-35. doi: 10.1016/j.critrevonc.2018.07.003. Epub 2018 Jul 18. Review.

PMID:
30196909
7.

Maintenance Treatment and Survival in Patients With Myeloma: A Systematic Review and Network Meta-analysis.

Gay F, Jackson G, Rosiñol L, Holstein SA, Moreau P, Spada S, Davies F, Lahuerta JJ, Leleu X, Bringhen S, Evangelista A, Hulin C, Panzani U, Cairns DA, Di Raimondo F, Macro M, Liberati AM, Pawlyn C, Offidani M, Spencer A, Hájek R, Terpos E, Morgan GJ, Bladé J, Sonneveld P, San-Miguel J, McCarthy PL, Ludwig H, Boccadoro M, Mateos MV, Attal M.

JAMA Oncol. 2018 Oct 1;4(10):1389-1397. doi: 10.1001/jamaoncol.2018.2961.

8.

Treatment Intensification With Autologous Stem Cell Transplantation and Lenalidomide Maintenance Improves Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma in Complete Response.

Mina R, Petrucci MT, Corradini P, Spada S, Patriarca F, Cerrato C, De Paoli L, Pescosta N, Ria R, Malfitano A, Musto P, Baldini L, Guglielmelli T, Gamberi B, Mannina D, Benevolo G, Zambello R, Falcone AP, Palumbo A, Nagler A, Calafiore V, Hájek R, Spencer A, Boccadoro M, Bringhen S.

Clin Lymphoma Myeloma Leuk. 2018 Aug;18(8):533-540. doi: 10.1016/j.clml.2018.05.019. Epub 2018 May 28.

PMID:
29910180
9.

hMENA isoforms impact NSCLC patient outcome through fibronectin/β1 integrin axis.

Di Modugno F, Spada S, Palermo B, Visca P, Iapicca P, Di Carlo A, Antoniani B, Sperduti I, Di Benedetto A, Terrenato I, Mottolese M, Gandolfi F, Facciolo F, Chen EI, Schwartz MA, Santoni A, Bissell MJ, Nisticò P.

Oncogene. 2018 Oct;37(42):5605-5617. doi: 10.1038/s41388-018-0364-3. Epub 2018 Jun 15.

10.

Exosomes Shuttle TREX1-Sensitive IFN-Stimulatory dsDNA from Irradiated Cancer Cells to DCs.

Diamond JM, Vanpouille-Box C, Spada S, Rudqvist NP, Chapman JR, Ueberheide BM, Pilones KA, Sarfraz Y, Formenti SC, Demaria S.

Cancer Immunol Res. 2018 Aug;6(8):910-920. doi: 10.1158/2326-6066.CIR-17-0581. Epub 2018 Jun 15.

11.

Maintenance in myeloma patients achieving complete response after upfront therapy: a pooled analysis.

Cerrato C, Di Raimondo F, De Paoli L, Spada S, Patriarca F, Crippa C, Mina R, Guglielmelli T, Ben-Yehuda D, Oddolo D, Nozzoli C, Angelucci E, Cascavilla N, Rizzi R, Rocco S, Baldini L, Ponticelli E, Marcatti M, Cangialosi C, Caravita T, Benevolo G, Ria R, Nagler A, Musto P, Tacchetti P, Corradini P, Offidani M, Palumbo A, Petrucci MT, Boccadoro M, Gay F.

J Cancer Res Clin Oncol. 2018 Jul;144(7):1357-1366. doi: 10.1007/s00432-018-2641-5. Epub 2018 Apr 19.

PMID:
29675792
12.

Once-weekly carfilzomib, pomalidomide, and low-dose dexamethasone for relapsed/refractory myeloma: a phase I/II study.

Bringhen S, Mina R, Cafro AM, Liberati AM, Spada S, Belotti A, Gaidano G, Patriarca F, Troia R, Fanin R, De Paoli L, Rossi G, Lombardo A, Bertazzoni P, Palumbo A, Sonneveld P, Boccadoro M.

Leukemia. 2018 Aug;32(8):1803-1807. doi: 10.1038/s41375-018-0024-1. Epub 2018 Jan 30. No abstract available.

PMID:
29479061
13.

IL-18 receptor marks functional CD8+ T cells in non-small cell lung cancer.

Timperi E, Focaccetti C, Gallerano D, Panetta M, Spada S, Gallo E, Visca P, Venuta F, Diso D, Prelaj A, Longo F, Facciolo F, Nisticò P, Barnaba V.

Oncoimmunology. 2017 May 12;6(7):e1328337. doi: 10.1080/2162402X.2017.1328337. eCollection 2017.

14.

IKAROS expression in distinct bone marrow cell populations as a candidate biomarker for outcome with lenalidomide-dexamethasone therapy in multiple myeloma.

Bolomsky A, Hübl W, Spada S, Müldür E, Schlangen K, Heintel D, Rocci A, Weißmann A, Fritz V, Willheim M, Zojer N, Palumbo A, Ludwig H.

Am J Hematol. 2017 Mar;92(3):269-278. doi: 10.1002/ajh.24634. Epub 2017 Feb 1.

15.

Matrin 3 variants are frequent in Italian ALS patients.

Marangi G, Lattante S, Doronzio PN, Conte A, Tasca G, Monforte M, Patanella AK, Bisogni G, Meleo E, La Spada S, Zollino M, Sabatelli M.

Neurobiol Aging. 2017 Jan;49:218.e1-218.e7. doi: 10.1016/j.neurobiolaging.2016.09.023. Epub 2016 Oct 6.

PMID:
28029397
16.

Autologous transplant vs oral chemotherapy and lenalidomide in newly diagnosed young myeloma patients: a pooled analysis.

Gay F, Oliva S, Petrucci MT, Montefusco V, Conticello C, Musto P, Catalano L, Evangelista A, Spada S, Campbell P, Ria R, Salvini M, Offidani M, Carella AM, Omedé P, Liberati AM, Troia R, Cafro AM, Malfitano A, Falcone AP, Caravita T, Patriarca F, Nagler A, Spencer A, Hajek R, Palumbo A, Boccadoro M.

Leukemia. 2017 Aug;31(8):1727-1734. doi: 10.1038/leu.2016.381. Epub 2016 Dec 23.

PMID:
28008174
17.

Neurological Involvement in the Course of Scleromyxedema: A Case Report.

Spagnolo F, Nozzoli C, Rini A, La Spada S, De Marco V, Passarella B.

J Stroke Cerebrovasc Dis. 2016 Sep;25(9):e148-50. doi: 10.1016/j.jstrokecerebrovasdis.2016.05.017. Epub 2016 Jun 6.

PMID:
27282303
18.

A phase 2 study of three low-dose intensity subcutaneous bortezomib regimens in elderly frail patients with untreated multiple myeloma.

Larocca A, Bringhen S, Petrucci MT, Oliva S, Falcone AP, Caravita T, Villani O, Benevolo G, Liberati AM, Morabito F, Montefusco V, Passera R, De Rosa L, Omedé P, Vincelli ID, Spada S, Carella AM, Ponticelli E, Derudas D, Genuardi M, Guglielmelli T, Nozzoli C, Aghemo E, De Paoli L, Conticello C, Musolino C, Offidani M, Boccadoro M, Sonneveld P, Palumbo A.

Leukemia. 2016 Jun;30(6):1320-6. doi: 10.1038/leu.2016.36. Epub 2016 Feb 22.

19.

Body experiences and psychopathology in idiopathic central precocious and early puberty.

Nacinovich R, Buzi F, Oggiano S, Rossi S, Spada S, Broggi F, Pilotta A, Neri F, Bomba M.

Minerva Pediatr. 2016 Feb;68(1):11-8.

PMID:
26864719
20.

[The Human Model, a tool for assessing preventive ergonomic postural appearance].

Spada S, Ghibaudo L, Sessa F, Varetto L, Cavatorta MP, Baracco A, Coggiola M, Romano C.

G Ital Med Lav Ergon. 2015 Jul-Sep;37(3):191-6. Italian.

PMID:
26749982
21.

Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.

Gay F, Oliva S, Petrucci MT, Conticello C, Catalano L, Corradini P, Siniscalchi A, Magarotto V, Pour L, Carella A, Malfitano A, Petrò D, Evangelista A, Spada S, Pescosta N, Omedè P, Campbell P, Liberati AM, Offidani M, Ria R, Pulini S, Patriarca F, Hajek R, Spencer A, Boccadoro M, Palumbo A.

Lancet Oncol. 2015 Dec;16(16):1617-29. doi: 10.1016/S1470-2045(15)00389-7. Epub 2015 Nov 17.

22.

hMENA(11a) contributes to HER3-mediated resistance to PI3K inhibitors in HER2-overexpressing breast cancer cells.

Trono P, Di Modugno F, Circo R, Spada S, Di Benedetto A, Melchionna R, Palermo B, Matteoni S, Soddu S, Mottolese M, De Maria R, Nisticò P.

Oncogene. 2016 Feb 18;35(7):887-96. doi: 10.1038/onc.2015.143. Epub 2015 May 11.

PMID:
25961924
23.

β1 and β4 integrins: from breast development to clinical practice.

Nisticò P, Di Modugno F, Spada S, Bissell MJ.

Breast Cancer Res. 2014;16(5):459. Review.

24.

Impact of three commercial feed formulations on farmed gilthead sea bream (Sparus aurata, L.) metabolism as inferred from liver and blood serum proteomics.

Ghisaura S, Anedda R, Pagnozzi D, Biosa G, Spada S, Bonaglini E, Cappuccinelli R, Roggio T, Uzzau S, Addis MF.

Proteome Sci. 2014 Sep 24;12(1):44. doi: 10.1186/s12953-014-0044-3. eCollection 2014.

25.

Identification, biological characterization and pharmacophoric analysis of a new potent and selective NK1 receptor antagonist clinical candidate.

Di Fabio R, Alvaro G, Braggio S, Carletti R, Gerrard PA, Griffante C, Marchioro C, Pozzan A, Melotto S, Poffe A, Piccoli L, Ratti E, Tranquillini E, Trower M, Spada S, Corsi M.

Bioorg Med Chem. 2013 Nov 1;21(21):6264-73. doi: 10.1016/j.bmc.2013.09.001. Epub 2013 Sep 11.

PMID:
24075145
26.

Multidisciplinary analytical investigation of phospholipids and triglycerides in offshore farmed gilthead sea bream (Sparus aurata) fed commercial diets.

Anedda R, Piga C, Santercole V, Spada S, Bonaglini E, Cappuccinelli R, Mulas G, Roggio T, Uzzau S.

Food Chem. 2013 Jun 1;138(2-3):1135-44. doi: 10.1016/j.foodchem.2012.11.098. Epub 2012 Dec 6.

PMID:
23411224
27.

Active home-based cancer treatment.

Bordonaro S, Raiti F, Di Mari A, Lopiano C, Romano F, Pumo V, Giuliano SR, Iacono M, Lanteri E, Puzzo E, Spada S, Tralongo P.

J Multidiscip Healthc. 2012;5:137-43. doi: 10.2147/JMDH.S31494. Epub 2012 Jun 19.

28.

Soft tissue depression at the iliac crest prominence: a new landmark for identifying the L4-L5 interspace.

Borghi B, Tognù A, White PF, Paolini S, Van Oven H, Aurini L, Mordenti A, Spada S, Bosco M.

Minerva Anestesiol. 2012 Dec;78(12):1348-56. Epub 2012 Jul 6.

29.

Discovery process and pharmacological characterization of a novel dual orexin 1 and orexin 2 receptor antagonist useful for treatment of sleep disorders.

Di Fabio R, Pellacani A, Faedo S, Roth A, Piccoli L, Gerrard P, Porter RA, Johnson CN, Thewlis K, Donati D, Stasi L, Spada S, Stemp G, Nash D, Branch C, Kindon L, Massagrande M, Poffe A, Braggio S, Chiarparin E, Marchioro C, Ratti E, Corsi M.

Bioorg Med Chem Lett. 2011 Sep 15;21(18):5562-7. doi: 10.1016/j.bmcl.2011.06.086. Epub 2011 Jun 30.

PMID:
21831639
30.

[The look into the look: how patients' suffering is perceived by health workers].

Bazzana E, Spada S, Braibanti P, Lembo A.

Urologia. 2011 Jan-Mar;78(1):60-6. Italian.

PMID:
21452162
31.

5-{2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}-2(1H)-quinolinones and 3,4-dihydro-2(1H)-quinolinones: dual-acting 5-HT1 receptor antagonists and serotonin reuptake inhibitors. Part 3.

Bromidge SM, Arban R, Bertani B, Borriello M, Capelli AM, Di-Fabio R, Faedo S, Gianotti M, Gordon LJ, Granci E, Pasquarello A, Spada SK, Worby A, Zonzini L, Zucchelli V.

Bioorg Med Chem Lett. 2010 Dec 1;20(23):7092-6. doi: 10.1016/j.bmcl.2010.09.085. Epub 2010 Sep 27.

PMID:
20951584
32.

Discovery of N-[(2S)-5-(6-fluoro-3-pyridinyl)-2,3-dihydro-1H-inden-2-yl]-2-propanesulfonamide, a novel clinical AMPA receptor positive modulator.

Ward SE, Harries M, Aldegheri L, Andreotti D, Ballantine S, Bax BD, Harris AJ, Harker AJ, Lund J, Melarange R, Mingardi A, Mookherjee C, Mosley J, Neve M, Oliosi B, Profeta R, Smith KJ, Smith PW, Spada S, Thewlis KM, Yusaf SP.

J Med Chem. 2010 Aug 12;53(15):5801-12. doi: 10.1021/jm1005429.

PMID:
20614889
33.

6-(3,4-dichlorophenyl)-1-[(methyloxy)methyl]-3-azabicyclo[4.1.0]heptane: a new potent and selective triple reuptake inhibitor.

Micheli F, Cavanni P, Andreotti D, Arban R, Benedetti R, Bertani B, Bettati M, Bettelini L, Bonanomi G, Braggio S, Carletti R, Checchia A, Corsi M, Fazzolari E, Fontana S, Marchioro C, Merlo-Pich E, Negri M, Oliosi B, Ratti E, Read KD, Roscic M, Sartori I, Spada S, Tedesco G, Tarsi L, Terreni S, Visentini F, Zocchi A, Zonzini L, Di Fabio R.

J Med Chem. 2010 Jul 8;53(13):4989-5001. doi: 10.1021/jm100481d.

PMID:
20527970
34.

End-of-life decision-making and quality of ICU performance: an observational study in 84 Italian units.

Bertolini G, Boffelli S, Malacarne P, Peta M, Marchesi M, Barbisan C, Tomelleri S, Spada S, Satolli R, Gridelli B, Lizzola I, Mazzon D.

Intensive Care Med. 2010 Sep;36(9):1495-504. doi: 10.1007/s00134-010-1910-9. Epub 2010 May 13.

PMID:
20464541
35.

Reliability of procalcitonin in neonatology. Experience in 59 preterm newborns.

Spada S, Cuccu A, Mussap M, Testa M, Puddu M, Pisu C, Burrai P, Fanos V.

J Matern Fetal Neonatal Med. 2009;22 Suppl 3:96-101. doi: 10.1080/14767050903195450.

PMID:
19925368
36.

[Stress in auto-transportation sector between prejudice and reality].

Ferranti A, Spada S, Mosconi G.

G Ital Med Lav Ergon. 2009 Apr-Jun;31(2):227-9. Italian.

PMID:
19827292
37.

Use of folding modulators to improve heterologous protein production in Escherichia coli.

Kolaj O, Spada S, Robin S, Wall JG.

Microb Cell Fact. 2009 Jan 27;8:9. doi: 10.1186/1475-2859-8-9.

38.

Synthesis and pharmacological characterization of novel druglike corticotropin-releasing factor 1 antagonists.

Di Fabio R, St-Denis Y, Sabbatini FM, Andreotti D, Arban R, Bernasconi G, Braggio S, Blaney FE, Capelli AM, Castiglioni E, Di Modugno E, Donati D, Fazzolari E, Ratti E, Feriani A, Contini S, Gentile G, Ghirlanda D, Provera S, Marchioro C, Roberts KL, Mingardi A, Mattioli M, Nalin A, Pavone F, Spada S, Trist DG, Worby A.

J Med Chem. 2008 Dec 11;51(23):7370-9. doi: 10.1021/jm800744m.

PMID:
18989952
39.

Dihydropyrrole[2,3-d]pyridine derivatives as novel corticotropin-releasing factor-1 antagonists: mapping of the receptor binding pocket by in silico docking studies.

Di Fabio R, Arban R, Bernasconi G, Braggio S, Blaney FE, Capelli AM, Castiglioni E, Donati D, Fazzolari E, Ratti E, Feriani A, Contini S, Gentile G, Ghirlanda D, Sabbatini FM, Andreotti D, Spada S, Marchioro C, Worby A, St-Denis Y.

J Med Chem. 2008 Nov 27;51(22):7273-86. doi: 10.1021/jm800743q.

PMID:
18975927
40.

Chiral tetrahydroquinoline derivatives as potent anti-hyperalgesic agents in animal models of sustained inflammation and chronic neuropathic pain.

Di Fabio R, Alvaro G, Bertani B, Donati D, Pizzi DM, Gentile G, Pentassuglia G, Giacobbe S, Spada S, Ratti E, Corsi M, Quartaroli M, Barnaby RJ, Vitulli G.

Bioorg Med Chem Lett. 2007 Mar 1;17(5):1176-80. Epub 2006 Dec 12.

PMID:
17218099
41.

Adsorption and activity of a domoic acid binding antibody fragment on mesoporous silicates.

Hu X, Spada S, White S, Hudson S, Magner E, Wall JG.

J Phys Chem B. 2006 Sep 21;110(37):18703-9.

PMID:
16970501
42.

Stiff person syndrome and motor mononeuropathy with conduction block: a singular association.

La Spada S, Negro C, Nozzoli C, De Marco V, Passarella B.

Clin Ter. 2006 May-Jun;157(3):237-9.

PMID:
16900850
43.

Synthesis and SAR of substituted tetrahydrocarbazole derivatives as new NPY-1 antagonists.

Di Fabio R, Giovannini R, Bertani B, Borriello M, Bozzoli A, Donati D, Falchi A, Ghirlanda D, Leslie CP, Pecunioso A, Rumboldt G, Spada S.

Bioorg Med Chem Lett. 2006 Mar 15;16(6):1749-52. Epub 2005 Dec 20.

PMID:
16364642
44.

Gastric cancer precursor lesions and Helicobacter pylori infection in patients with partial gastrectomy for peptic ulcer.

Giuliani A, Caporale A, Demoro M, Benvenuto E, Scarpini M, Spada S, Angelico F.

World J Surg. 2005 Sep;29(9):1127-30.

PMID:
16096865
45.

Weekly docetaxel and gemcitabine as first-line treatment for metastatic breast cancer: results of a multicenter phase II study.

Palmeri S, Vaglica M, Spada S, Filippelli G, Farris A, Palmeri L, Massidda B, Misino A, Ferraù F, Comella G, Leonardi V, Condemi G, Mangiameli A, De Cataldis G, Macaluso MC, Cajozzo M, Iannitto E, Danova M.

Oncology. 2005;68(4-6):438-45. Epub 2005 Jul 14. Review.

PMID:
16020974
46.

[Exercise-induced left arm pain and thrombocytosis].

Kunz I, Spada S, Sütsch G, Ruggieri F.

Praxis (Bern 1994). 2005 Apr 13;94(15):599-603. German.

PMID:
15884726
47.

Acroparesthesia and acral arterial occlusions as first manifestations of essential thrombocythemia.

Husmann MJ, Romer GS, Amann-Vesti BR, Spada S, Koppensteiner R.

Vasa. 2005 Feb;34(1):53-6.

PMID:
15786940
48.

Influence of air pollution on chronic obstructive respiratory diseases: comparison between city (Rome) and hillcountry environments and climates.

Avino P, De Lisio V, Grassi M, Lucchetra MC, Messina B, Monaco G, Petraccia L, Quartieri G, Rosentzwig R, Russo MV, Spada S, Valenzi VI.

Ann Chim. 2004 Sep-Oct;94(9-10):629-35.

PMID:
15506613
49.

Detection of conjugated C16 PUFAs in rat tissues as possible partial beta-oxidation products of naturally occurring conjugated linoleic acid and its metabolites.

Banni S, Petroni A, Blasevich M, Carta G, Angioni E, Murru E, Day BW, Melis MP, Spada S, Ip C.

Biochim Biophys Acta. 2004 Jun 1;1682(1-3):120-7.

PMID:
15158763
50.

Cancer precursor lesions in intact stomach Helicobacter pylori gastritis and in resected stomach gastritis.

Giuliani A, Spada S, Corona M, Demoro M, Di Bari M, Ricciardulli T, Galati G, Caporale A, Tocchi A, Angelico F.

J Exp Clin Cancer Res. 2003 Sep;22(3):371-8.

PMID:
14582693

Supplemental Content

Support Center